PI3K-delta Inhibitor SHC014748M clinical trials
Also written SHC014748M.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2018
How each study uses PI3K-delta Inhibitor SHC014748M is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- SHC014748M
- 2
Studies by the year they started
4 studies that test it; most in 2020 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses PI3K-delta Inhibitor SHC014748M is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Efficacy and Safety of SHC014748M in Patients With Relapsed or Refractory Follicular (FL) or Marginal Zone (MZL) LymphomaStatus unknownPhase 2Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04431089Written as SHC014748MHow we know
- A Study of SHC014748M in Patients With Relapsed or Refractory Peripheral T Cell LymphomaStatus unknownPhase 2Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04470141Written as SHC014748M treatmentHow we know
- A Food-Effect Study of SHC014748M in Healthy SubjectsStatus unknownPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT04006860Written as SHC014748M CapsulesHow we know
- Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic MalignanciesStatus unknownPhase 1Nanjing Sanhome Pharmaceutical, Co., Ltd.NCT03588598Written as SHC014748MHow we know